【24h】

Adjustable thermoplastic mandibular advancement device for obstructive sleep apnea: Outcomes and practicability

机译:用于阻塞性睡眠呼吸暂停的可调节热塑性下颌前移装置:结果和实用性

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives/Hypothesis: To assess outcomes including efficacy, adverse effects, and quality of life (QOL) of an adjustable thermoplastic mandibular advancement device (AT-MAD) fitted by an otolaryngologist for obstructive sleep apnea (OSA) treatment. Study Design: Prospective, nonrandomized, before-after study. Methods: Sixty-four adult patients (40 men and 24 women) were recruited. Inclusion criteria were OSA patients who had failed or refused treatment with continuous positive airway pressure and surgery. Exclusion criteria were insufficient teeth, active intraoral disease, and temporomandibular joint (TMJ) disorders. Outcomes were measured using polysomnography, symptom questionnaires, Epworth Sleepiness Scale (ESS), and Functional Outcomes of Sleep Questionnaire (FOSQ) before treatment and 4 to 6 months thereafter. Results: Mean apnea-hypopnea index (AHI) and ESS scores decreased from 17.7 ± 14.6 to 7.5 ± 10.9 and from 8.7 ± 4.9 to 6.5 ± 4.4, respectively, after treatment (P < .001). Thirty-nine patients (60.9%) achieved post-treatment AHI of <5, with the highest success rate in those with mild OSA (75%). FOSQ global scores increased from 16.4 ± 2.8 to 17.7 ± 3.0 (P < .05), along with most FOSQ subscale scores. Thirty-four patients (53.1%) regularly used the device for ≥5 nights per week. Adverse effects include TMJ discomfort, dry mouth, and excessive salivation, which were largely tolerable. Only four patients withdrew from the study because of adverse effects. Conclusions: This is the first study in Asians demonstrating that an AT-MAD, if done properly, is a practical short-term treatment of OSA, with good outcomes including improved QOL. Its advantages are its low cost and ready-to-use nature. However, further randomized controlled trials are required.
机译:目的/假设:评估由耳鼻喉科医生安装的可调节热塑性下颌前移装置(AT-MAD)的疗效,不良反应和生活质量(QOL)的结局,以进行阻塞性睡眠呼吸暂停(OSA)治疗。研究设计:前瞻性,非随机,前后研究。方法:招募了64名成人患者(40名男性和24名女性)。纳入标准为持续气道正压通气和手术治疗失败或拒绝治疗的OSA患者。排除标准为牙齿不足,活动性口腔内疾病和颞下颌关节(TMJ)障碍。治疗前和治疗后4至6个月使用多导睡眠监测仪,症状问卷,Epworth嗜睡量表(ESS)和睡眠问卷功能结果(FOSQ)对结果进行测量。结果:治疗后平均呼吸暂停低通气指数(AHI)和ESS评分分别从17.7±14.6降至7.5±10.9和8.7±4.9降至6.5±4.4(P <.001)。三十九名患者(60.9%)的治疗后AHI低于5,在轻度OSA患者中成功率最高(75%)。 FOSQ整体评分与大多数FOSQ子量表评分一样,从16.4±2.8增至17.7±3.0(P <.05)。每周有34例患者(53.1%)定期使用该设备≥5晚。不良反应包括TMJ不适,口干和流涎过多,这在很大程度上是可以忍受的。由于不良反应,只有四名患者退出研究。结论:这是亚洲人中的第一项研究,证明AT-MAD如果操作正确,是OSA的实用短期治疗方法,具有良好的疗效,包括改善的QOL。它的优点是低成本和即用型。但是,还需要进一步的随机对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号